MCL1 Recombinant antibody

MCL1 Recombinant Antibody for WB, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

Human

Applications

WB, ELISA

Conjugate

Unconjugated

CloneNo.

5P13

Cat no : 82695-4-RR

Synonyms

EAT, Mcl 1, Mcl 1l, Mcl 1s Delta TM, MCL1, mcl1/EAT, MCL1L, MCL1S, TM

---

Validation Data Gallery

• 

  WB analysis using 82695-4-RR

  Various lysates were subjected to SDS PAGE followed by western blot with 82695-4-RR (MCL1 antibody) at dilution of 1:5000 incubated at room temperature for 1.5 hours.

---

Tested Applications

• Positive WB detected in: HeLa cells, HEK-293 cells, MDA-MB-231 cells, Jurkat cells, Raji cells

Recommended dilution

• Western Blot (WB): WB : 1:2000-1:10000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, Check data in validation data gallery.

Product Information

82695-4-RR targets MCL1 in WB, ELISA applications and shows reactivity with Human samples.

• Tested Reactivity: Human
• Host / Isotype: Rabbit / IgG
• Class: Recombinant
• Type: Antibody
• Immunogen: MCL1 fusion protein Ag10397
• Full Name: myeloid cell leukemia sequence 1 (BCL2-related)
• Calculated Molecular Weight: 350 aa, 37 kDa
• Observed Molecular Weight: 40 kDa
• GenBank Accession Number: BC107735
• Gene Symbol: MCL1
• Gene ID (NCBI): 4170
• Conjugate: Unconjugated
• Form: Liquid
• Purification Method: Protein A purification
• Storage Buffer: PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
• Storage Conditions: Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20^oC storage. 20ul sizes contain 0.1% BSA.

Background Information

MCL-1 is an anti-apoptotic member of the Bcl-2 family originally isolated from the ML-1 human myeloid leukemia cell line. Similar to BCL2 and BCL2L1, MCL1 can interact with BAX and/or BAK1 to inhibit mitochondria-mediated apoptosis. Mcl-1 is critical for the proliferation and survival of myeloma cells in vitro, and overexpression of Mcl-1 protein in myeloma cells is associated with relapse and short event-free survival in multiple myeloma patients. Recent studies show that MCL-1 is upregulated in numerous haematological and solid tumor malignancies. Therefore, MCL-1 has been suggested as a potential new therapeutic target. MCL-1 can be alternatively spliced into a long form (MCL-1L, 40 kDa) or a short form (MCL-1S, 30 kDa). (PMID: 15467463, PMID: 15147382)